NIOX Group PLC

Company Profile

• Business description

  NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).

• Contact

  1 Robert Robinson Avenue
  Magdalen Centre
  The Oxford Science Park
  OxfordOX4 4GA
  GBR

  T: +44 3303309356

  E: [email protected]

  https://www.niox.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Medical Devices

  Fiscal Year End

  31 December 2026

  Employees

  97